Page 61 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

SDIRSACR Oncology Insights

biopsies can offer insights into tumor dynamics without the need for invasive tissue sampling. This techniqueis
particularly useful for monitoring treatment response, detecting minimal residual disease, and identifying emerging
resistance mutations.

2. Immunotherapy and Immune Profiling
Immunotherapy represents a paradigm shift in cancer treatment. Therapies such as immune checkpoint inhibitors
(e.g., PD-1/PD-L1blockers) have shown remarkable success in cancers like melanoma, lung cancer, and bladder cancer.
However, not all patients benefit. Ongoing research is focused on identifying immune-related biomarkers, such as
tumor mutational burden (TMB) and PD-L1 expression levels, to predict which patients are most likely to respond.
In the future, tumor immune microenvironment profiling may become standard practice in guiding immunotherapy
decisions.

3. Targeted Therapies and Precision Oncology
Targeted therapies aim to block the activity of molecules essential for tumor survival and growth. The success of agents
like imatinib in chronic myeloid leukemia (targeting BCR-ABL fusion protein) and vemurafenib in BRAF-mutant melanoma
illustrates the power of this approach. The ongoing development of next-generation sequencing (NGS) technologies is
enabling the identification of rare but actionable mutations, allowing patients with previously untreatable cancers to
receive effective, targeted drugs.

4. Epigenetic Therapies and Gene Editing
Alterations in DNA methylation, histone modification, and non-coding RNA expression play crucial roles in cancer. New
therapeutic strategies aim to reverse these changes using epigenetic drugs, suchas DNA methyltransferase inhibitors
or histone deacetylase inhibitors. In addition, CRISPR-Cas9 gene editing technology is being explored to directly correct
genetic defects or disrupt oncogenes, although clinical application is still in the early stages.

5. Artificial Intelligence (AI) and Big Data in Cancer Genomics
With the explosion of genomic and clinical data, AI is becoming an essential tool in oncology. Machine learning algorithms
can analyze complex molecular data to predict disease progression, treatment response, and survival outcomes. AI is
also accelerating drug discovery by identifying novel therapeutic targets based on large-scale cancer genome datasets.

6. Multi-Omics Integration
A single type of data, such as genomics alone, is often insufficient to fully capture the complexity of cancer. Therefore,
integrating multi-omics approaches—including genomics, transcriptomics, proteomics, and metabolomics—is
becoming increasingly important. This comprehensive view enables researchers to uncover novel pathways and
interactions that contribute to tumor behavior, opening doors to more effective combination therapies.

7. Combination Therapy Strategies
Cancer cells often develop resistance to monotherapies. As a result, combining therapies with different mechanisms
of action is gain ingtraction. For example, combining immune checkpoint inhibitors with targeted therapies or
chemotherapy has improved survival in several cancers. Rationally designed combination regimens based on tumor
biology are expected to enhance efficacy and overcome resistance.

Challenges and Ethical Considerations. Despite the promise of molecular oncology, several challenges remain. Tumor
heterogeneity, both between patients (intertumoral) and within a single tumor (intratumoral), complicates diagnosis
and treatment. Additionally, access to high-end molecular testing is often limited by cost and infrastructure, especially in
low-resource settings. Ethical issues also arise, particularly with genomic testing. The discovery of incidental findings—
mutations unrelated to the current cancer but relevant to future health—raises questions about disclosure and genetic
counseling. Data privacy and informed consent are also critical concerns in the age of precision medicine.

Conclusion. Tumor typing is not just a scientific advancement—it is a clinical necessity. By revealing the molecular
intricacies of each tumor, it guides the selection of targeted, effective therapies and paves the way for truly personalized
cancer care. As molecular biology tools continue to evolve, we move closer to an era in which cancer treatment is guided
not by where the tumor originated, but by the unique molecular fingerprint it carries. From non-invasive diagnostics
and immunotherapies to AI-powered genomic analysis and multi-omics integration, the future of oncologyis one of
precision, personalization, and possibility. Continued investment in research, technology, and equitable access will be
key to ensuring that these innovations benefit all cancer patients, regardless of geography or background.

46